Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons

We recently reported that prepulse inhibition (PPI) in humans was increased by the dopamine (DA) agonist/ N-methyl- D-aspartate (NMDA) antagonist amantadine (200 mg), but was not significantly altered by the DA agonist bromocriptine (1.25-2.5 mg). PPI-enhancing effects of DA agonists occur in rats u...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Psychopharmacologia 2002-10, Vol.164 (1), p.82-92
Hauptverfasser:	SWERDLOW, Neal R, STEPHANY, Nora, SHOEMAKER, Jody M, ROSS, Laura, WASSERMAN, Lindsay C, TALLEDO, Jo, AUERBACH, Pamela P
Format:	Artikel
Sprache:	eng
Schlagworte:	Acoustic Stimulation - methods Adult Amantadine - pharmacology Analysis of Variance Animals Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Bromocriptine - pharmacology Dose-Response Relationship, Drug Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Psychomotor Performance - drug effects Psychomotor Performance - physiology Rats Rats, Sprague-Dawley Reflex, Startle - drug effects Reflex, Startle - physiology Species Specificity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We recently reported that prepulse inhibition (PPI) in humans was increased by the dopamine (DA) agonist/ N-methyl- D-aspartate (NMDA) antagonist amantadine (200 mg), but was not significantly altered by the DA agonist bromocriptine (1.25-2.5 mg). PPI-enhancing effects of DA agonists occur in rats under specific stimulus conditions, including short prepulse intervals (
ISSN:	0033-3158 1432-2072
DOI:	10.1007/s00213-002-1172-5